Lantus
Mylan and Biocon’s Semglee, biosimilar to Sanofi’s Lantus, approved by FDA for type 1 and 2 diabetes
June 12, 2020Medical Communications, Sales and Marketing FDA, Lantus, Mylan Biocon, Sanofi, Semglee, diabetes
Mylan and Biocon have scored FDA approval with their insulin glargine injection Semglee, a biosimilar to Sanofi’s Lantus, in both …
MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes
October 15, 2018Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma
MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …
Sanofi Q3 results disappoint due to waning diabetes sales
November 2, 2017Sales and Marketing Lantus, Sanofi, diabetes, pharma
Sanofi readjusted its 2017 financial expectations after its third-quarter results came in lower than projected. The company revealed that net …
Sanofi launches patent infringement lawsuit against Mylan over diabetes pen
October 25, 2017Research and Development, Sales and Marketing Basaglar, Eli Lilly, Lantus, Mylan, Sanofi, diabetes, insulin, patent infringement, pharma
Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …
Sanofi reveals promising data for FDA-delayed diabetes drug
September 14, 2016Research and Development, Sales and Marketing FDA, Lantus, Sanofi, iglarlixi
Sanofi has announced new Phase III data for its IGlarLixi combination drug for the treatment of diabetes, showing it could …
MSD files Lantus biosimilar with FDA
August 8, 2016Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar
MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …
FDA to decide on Sanofi diabetes combo
February 22, 2016Research and Development, Sales and Marketing Lantus, Sanofi
Sanofi will be looking to August for a decision on its new type 2 diabetes combo LixiLan (lixisenatide and Lantus), …
FDA approves Lilly/Boehringer Lantus biosimilar
December 17, 2015Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly
The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …
Sanofi’s LixiLan meets target in Phase III diabetes trial
September 16, 2015Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes
Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …
Lilly and Boehringer launch biosimilar insulin in the UK
August 26, 2015Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly
Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …
Sanofi launches new insulin Toujeo in the UK
August 4, 2015Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo
Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …
Sanofi rules out Toujeo discount in diabetes
April 14, 2015Sales and Marketing 100 U/mL, Boehringer, Lantus, insulin glargine [rDNA origin] injection, lilly, toujeo
Sanofi has revealed that it will not discount its new insulin Toujeo more than its current blockbuster Lantus, despite lacking …
Sanofi sales lifted by diabetes and rare diseases
February 6, 2015Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4
Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …
France Focus: Power without responsibility?
October 27, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing France, Lantus, Sanofi, Servier, hollande, perindopril, report
Population: 65.8 million (2013) Government: Unitary semi-presidential constitutional republic Leader: François Hollande of the centre-left Socialist Party Gross Domestic Product: …
Lilly and Boehringer diabetes biosimilar sees EU approval
September 11, 2014Sales and Marketing Boehringer, EU, European Commission, Lantus, Sanofi, diabetes, lilly
Lilly and Boehringer Ingelheim’s insulin glargine product has been shown the green light by the European Commission (EC). The copycat …
Latest content
FibroFind appoints Lee Borthwick as CEO
